360 related articles for article (PubMed ID: 12664069)
1. Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels.
Gotanda K; Shinbo A; Okada M; Nakano Y; Kobayashi H; Sasaki T; Hagiwara M; Akaza H
Prostate Cancer Prostatic Dis; 2003; 6(1):66-72. PubMed ID: 12664069
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by leuprorelin, a luteinizing hormone-releasing hormone agonist.
Said MM; Hokaiwado N; Tang M; Ogawa K; Suzuki S; Ghanem HM; Esmat AY; Asamoto M; Refaie FM; Shirai T
Cancer Sci; 2006 Jun; 97(6):459-67. PubMed ID: 16734723
[TBL] [Abstract][Full Text] [Related]
3. Suppressive effects of the antiandrogen agent, chlormadinone acetate and the 5alpha-reductase inhibitor, dutasteride on prostate weight and intraprostatic androgen levels in rats.
Kobayashi H; Gotanda K; Shibata Y; Watanabe J; Nakano Y; Shinbo A; Suzuki K
Arzneimittelforschung; 2011; 61(9):515-20. PubMed ID: 22029228
[TBL] [Abstract][Full Text] [Related]
4. [Pretreatment with chlormadinone acetate in prostate cancer patients treated with a luteinizing hormone-releasing hormone analogue].
Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
Hinyokika Kiyo; 1998 Aug; 44(8):557-63. PubMed ID: 9783191
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients.
Ohuchi H; Noguchi K; Kinoshita Y; Hosaka M; Kawasaki C; Miura T; Kondo I; Harada M
Hinyokika Kiyo; 2000 Aug; 46(8):531-6. PubMed ID: 11019371
[TBL] [Abstract][Full Text] [Related]
6. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
Lamberts SW; Uitterlinden P; de Jong FH
Cancer Res; 1988 Nov; 48(21):6063-8. PubMed ID: 2844399
[TBL] [Abstract][Full Text] [Related]
7. Decrease of genital organ weights and plasma testosterone levels in rats following oral administration of leuprolide microemulsion.
Zheng JY; Fulu MY
Int J Pharm; 2006 Jan; 307(2):209-15. PubMed ID: 16300912
[TBL] [Abstract][Full Text] [Related]
8. Prevention of the initial testosterone surge induced by a luteinizing hormone-releasing hormone analogue in prostate cancer patients: the endocrinological effects of pretreatment with chlormadinone acetate.
Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
J Med Invest; 1999 Feb; 46(1-2):55-8. PubMed ID: 10408158
[TBL] [Abstract][Full Text] [Related]
9. [Clinical study on chlormadinone acetate alone followed by combination with LH-RH analogue for prostatic cancer: effects on lipid metabolism].
Shimada M; Uchida H; Kasahara T; Fuji K; Ogawa Y; Yoshida H; Hamajima T; Matsuda N; Ikeuchi T; Kai Y; Hiramori M; Hoshino M; Inoue K; Higaki Y
Hinyokika Kiyo; 1998 Jul; 44(7):525-32. PubMed ID: 9752613
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of testosterone production with ketoconazole alone and in combination with a gonadotropin releasing hormone analogue in the rat.
English HF; Santner SJ; Levine HB; Santen RJ
Cancer Res; 1986 Jan; 46(1):38-42. PubMed ID: 3079588
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of chlormadinone acetate-pellet implantation and orchidectomy on benign prostatic hypertrophy in the dog.
Kawakami E; Tsutsui T; Shimizu M; Orima H; Fujita M; Ogasa A
Int J Androl; 1995 Oct; 18(5):248-55. PubMed ID: 8567095
[TBL] [Abstract][Full Text] [Related]
12. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
13. [Hormonal environment following treatment with a small dose of estrogen--small dose of estrogen alone and in combination with an anti-androgen].
Hayashi T; Taki Y; Ikai K; Hiura M; Kiriyama T
Hinyokika Kiyo; 1987 Jul; 33(7):1035-42. PubMed ID: 2446483
[TBL] [Abstract][Full Text] [Related]
14. Effect of antiandrogen, chlormadinone acetate (CMA), in canine spontaneous benign prostatic hyperplasia (BPH).
Murakoshi M; Ikada R; Tagawa M; Nakayama T
Tokai J Exp Clin Med; 2000 Apr; 25(1):11-4. PubMed ID: 11023050
[TBL] [Abstract][Full Text] [Related]
15. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
[TBL] [Abstract][Full Text] [Related]
16. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic profiles of investigational kisspeptin/metastin analogues, TAK-448 and TAK-683, in adult male rats in comparison to the GnRH analogue leuprolide.
Matsui H; Masaki T; Akinaga Y; Kiba A; Takatsu Y; Nakata D; Tanaka A; Ban J; Matsumoto S; Kumano S; Suzuki A; Ikeda Y; Yamaguchi M; Watanabe T; Ohtaki T; Kusaka M
Eur J Pharmacol; 2014 Jul; 735():77-85. PubMed ID: 24747751
[TBL] [Abstract][Full Text] [Related]
18. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of a parenteral testosterone microsphere formulation in the male rat. Demonstration of dose dependence and controlled release.
Peacock NR; Swerdloff RS; Berman N; Gilley RM; Tice TR; Bhasin S
J Androl; 1993; 14(1):45-52. PubMed ID: 8473236
[TBL] [Abstract][Full Text] [Related]
20. Histopathological and immunocytochemical studies of chlormadinone acetate on the rat prostate.
Murakoshi M; Ikeda R; Fukui N; Tagawa M
Tokai J Exp Clin Med; 2002 Dec; 27(4):91-5. PubMed ID: 12713012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
